Drugs / PPI-2458
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00100347 | Dec 2004 → Jul 2007 | cancer, non-Hodgkin lymphoma | PRAECIS Pharmaceuticals Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PPI-2458 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00100347 ↗ |
| Action | Inhibit | “maximally inhibits MetAP2” NCT00100347 ↗ |
| Modality | Small molecule | — CHEMBL3527358 ↗ |
| Target | METAP2 | “maximally inhibits MetAP2” NCT00100347 ↗ |